Thursday 15 October 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.67
0.06
+9.84%
Follow IVVD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.78 | 7.21 | 7.96 | 3.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.48) | (9.65) | (27.52) | (22.69) | |
P/B ratio |
1.54 | 1.98 | 1.76 | 2.01 | |
Price to Tangible BV |
1.54 | 1.98 | 1.76 | 2.01 | |
EV/Sales |
2.03 | 3.91 | 3.72 | 2.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.09) | (2.77) | (3.42) | (1.27) | |
EV/FCF |
(1.08) | (2.75) | (3.41) | (1.27) | |
Quick Ratio |
5.52 | 6.18 | 7.04 | 2.13 | |
Current Ratio |
5.87 | 6.47 | 7.24 | 2.47 | |
Net Debt/EBITDA |
3.54 | 4.32 | 18.70 | 8.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.38 | 0.32 | 0.26 | 0.33 | |
Operating CF/Net income |
0.97 | 1.01 | 1.40 | 0.79 | |
Capex/Depreciation |
(0.80) | (1.42) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
205.58% | 223.60% | 58.39% | 61.28% | |
Selling, General and Administrative Expense of Revenue |
206.27% | 182.75% | 107.94% | 114.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.27% | 19.62% | 14.90% | 23.41% | |
Graham Net Nets |
0.52 | 0.41 | 0.50 | 0.34 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(37.93%) | (23.85%) | (12.96%) | (42.73%) | |
Free Cash Flow Yield |
(39.34%) | (19.74%) | (13.70%) | (42.97%) | |
Revenue per Share |
0.04 | 0.04 | 0.10 | 0.08 | |
Operating CF per Share |
(0.13) | (0.13) | (0.09) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.14) | (0.09) | (0.05) | |
Cash per Share |
0.50 | 0.59 | 1.32 | 0.50 | |
Shareholders Equity per Share |
0.57 | 0.66 | 1.40 | 0.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.57 | 0.66 | 1.40 | 0.55 | |
Free Cash Flow |
(43.51) | (42.44) | (15.45) | (8.25) | |
Working Capital |
151.08 | 173.26 | 213.30 | 65.27 | |
Capital Expenditures |
(0.51) | (0.73) | 0.00 | 0.00 | |
Net Current Asset Value |
144.31 | 166.22 | 212.12 | 63.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.96 | 10.10 | 12.41 | 9.00 | |
Average Payables |
13.77 | 5.38 | 12.10 | 17.91 | |
Average Assets |
154.01 | 172.74 | 203.20 | 150.54 | |
Average Common Equity |
111.93 | 128.60 | 154.54 | 88.11 |
Columns are period end dates